Literature DB >> 22293569

The critical impact of time discounting on economic incentives to overcome the antibiotic market failure.

Brad Spellberg, Priya Sharma, John H Rex.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22293569      PMCID： PMC3883457          DOI： 10.1038/nrd3560-c1

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  8 in total

1.  Putting a price on biotechnology.

Authors:  J J Stewart; P N Allison; R S Johnson
Journal:  Nat Biotechnol       Date:  2001-09       Impact factor: 54.908

2.  The price of innovation: new estimates of drug development costs.

Authors:  Joseph A DiMasi; Ronald W Hansen; Henry G Grabowski
Journal:  J Health Econ       Date:  2003-03       Impact factor: 3.883

3.  Antibacterial R&D incentives.

Authors:  Ramanan Laxminarayan; John H Powers
Journal:  Nat Rev Drug Discov       Date:  2011-09-30       Impact factor: 84.694

Review 4.  How to improve R&D productivity: the pharmaceutical industry's grand challenge.

Authors:  Steven M Paul; Daniel S Mytelka; Christopher T Dunwiddie; Charles C Persinger; Bernard H Munos; Stacy R Lindborg; Aaron L Schacht
Journal:  Nat Rev Drug Discov       Date:  2010-02-19       Impact factor: 84.694

5.  Discounting and decision making in the economic evaluation of health-care technologies.

Authors:  Karl Claxton; Mike Paulden; Hugh Gravelle; Werner Brouwer; Anthony J Culyer
Journal:  Health Econ       Date:  2010-05-12       Impact factor: 3.046

6.  Discounting health effects in pharmacoeconomic evaluations: current controversies.

Authors:  J M Bos; Maarten J Postma; Lieven Annemans
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

7.  Combating antimicrobial resistance: policy recommendations to save lives.

Authors:  Brad Spellberg; Martin Blaser; Robert J Guidos; Helen W Boucher; John S Bradley; Barry I Eisenstein; Dale Gerding; Ruth Lynfield; L Barth Reller; John Rex; David Schwartz; Edward Septimus; Fred C Tenover; David N Gilbert
Journal:  Clin Infect Dis       Date:  2011-05       Impact factor: 9.079

8.  Quantifying the dream: valuation approaches in biotechnology.

Authors:  S Papadopoulos
Journal:  Nat Biotechnol       Date:  1998-05       Impact factor: 54.908
  8 in total
  11 in total

1.  The FDA reboot of antibiotic development.

Authors:  David M Shlaes; Dan Sahm; Carol Opiela; Brad Spellberg
Journal:  Antimicrob Agents Chemother       Date:  2013-07-29       Impact factor: 5.191

2.  Challenges and solutions for clinical development of new antibacterial agents: results of a survey among pharmaceutical industry professionals.

Authors:  Esther Bettiol; Jeffrey D Wetherington; Nicola Schmitt; Stephan Harbarth
Journal:  Antimicrob Agents Chemother       Date:  2015-04-27       Impact factor: 5.191

Review 3.  Novel approaches are needed to develop tomorrow's antibacterial therapies.

Authors:  Brad Spellberg; John Bartlett; Rich Wunderink; David N Gilbert
Journal:  Am J Respir Crit Care Med       Date:  2015-01-15       Impact factor: 21.405

4.  Meeting the societal need for new antibiotics: the challenges for the pharmaceutical industry.

Authors:  Seamus O'Brien
Journal:  Br J Clin Pharmacol       Date:  2015-02       Impact factor: 4.335

Review 5.  The future of antibiotics.

Authors:  Brad Spellberg
Journal:  Crit Care       Date:  2014-06-27       Impact factor: 9.097

Review 6.  The evolution of the regulatory framework for antibacterial agents.

Authors:  John H Rex; Mark Goldberger; Barry I Eisenstein; Carrie Harney
Journal:  Ann N Y Acad Sci       Date:  2014-05-02       Impact factor: 5.691

7.  Bulgecin A as a β-lactam enhancer for carbapenem-resistant Pseudomonas aeruginosa and carbapenem-resistant Acinetobacter baumannii clinical isolates containing various resistance mechanisms.

Authors:  Marion J Skalweit; Mei Li
Journal:  Drug Des Devel Ther       Date:  2016-09-20       Impact factor: 4.162

Review 8.  Management options for reducing the release of antibiotics and antibiotic resistance genes to the environment.

Authors:  Amy Pruden; D G Joakim Larsson; Alejandro Amézquita; Peter Collignon; Kristian K Brandt; David W Graham; James M Lazorchak; Satoru Suzuki; Peter Silley; Jason R Snape; Edward Topp; Tong Zhang; Yong-Guan Zhu
Journal:  Environ Health Perspect       Date:  2013-06-04       Impact factor: 9.031

9.  Incentives for new antibiotics: the Options Market for Antibiotics (OMA) model.

Authors:  David M Brogan; Elias Mossialos
Journal:  Global Health       Date:  2013-11-07       Impact factor: 4.185

Review 10.  β-Lactam Antibiotics Renaissance.

Authors:  Wenling Qin; Mauro Panunzio; Stefano Biondi
Journal:  Antibiotics (Basel)       Date:  2014-05-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.